This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klepser, M. E.
Right arrow Articles by Pfaller, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klepser, M. E.
Right arrow Articles by Pfaller, M. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2000, p. 1917-1920, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology

Michael E. Klepser,1,* Dennis Malone,1 Russell E. Lewis,1 Erika J. Ernst,1 and Michael A. Pfaller2

University of Iowa Colleges of Pharmacy1 and Medicine,2 Iowa City, Iowa 52242

Received 11 January 2000/Returned for modification 10 April 2000/Accepted 21 April 2000

Voriconazole is an investigational azole antifungal agent with activity against a variety of fungal species, including fluconazole-susceptible and -resistant Candida species and Cryptococcus neoformans. In this study, we employed in vitro time-kill methods to characterize the relationship between concentrations of voriconazole and its fungistatic activity against Candida albicans, Candida glabrata, Candida tropicalis, and C. neoformans. Isolates were exposed to voriconazole concentrations ranging from 0.0625 to 16 times the MIC, and the viable colony counts were determined over time. The 50 and 90% effective concentrations (EC50 and EC90, respectively) were determined at 8, 12, and 24 h following the addition of voriconazole. At each time point, near-maximal fungistatic activity, as indicated by the EC90, was noted at a drug concentration of approximately three times the MIC. Additionally, EC50 and EC90 did not change over time, thus suggesting that the rate of activity was not improved by increasing concentrations. Voriconazole exhibits non-concentration-dependent pharmacodynamic characteristics in vitro.

* Corresponding author. Mailing address: S412 Pharmacy Bldg., University of Iowa College of Pharmacy, Iowa City, IA 52242-1112. Phone: (319) 335-8861. Fax: (319) 353-5646. E-mail: michael-klepser{at}uiowa.edu.

Antimicrobial Agents and Chemotherapy, July 2000, p. 1917-1920, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Li, Y., Nguyen, M. H., Derendorf, H., Cheng, S., Clancy, C. J. (2007). Measurement of Voriconazole Activity against Candida albicans, C. glabrata, and C. parapsilosis Isolates Using Time-Kill Methods Validated by High-Performance Liquid Chromatography. Antimicrob. Agents Chemother. 51: 2985-2987 [Abstract] [Full Text]  
  • Shen, Y.-C., Wang, M.-Y., Wang, C.-Y., Tsai, T.-C., Tsai, H.-Y., Lee, Y.-F., Wei, L.-C. (2007). Clearance of Intravitreal Voriconazole. IOVS 48: 2238-2241 [Abstract] [Full Text]  
  • Ballesta, S., Garcia, I., Perea, E. J., Pascual, A. (2005). Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother 55: 785-787 [Abstract] [Full Text]  
  • Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A. (2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev. 18: 163-194 [Abstract] [Full Text]  
  • Pfaller, M. A., Sheehan, D. J., Rex, J. H. (2004). Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization. Clin. Microbiol. Rev. 17: 268-280 [Abstract] [Full Text]  
  • Gunderson, S. M., Hayes, R. A., Quinn, J. P., Danziger, L. H. (2004). In Vitro Pharmacodynamic Activities of ABT-492, a Novel Quinolone, Compared to Those of Levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 48: 203-208 [Abstract] [Full Text]  
  • Rogers, P. D., Barker, K. S. (2003). Genome-Wide Expression Profile Analysis Reveals Coordinately Regulated Genes Associated with Stepwise Acquisition of Azole Resistance in Candida albicans Clinical Isolates. Antimicrob. Agents Chemother. 47: 1220-1227 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Rogers, P. D., Barker, K. S. (2002). Evaluation of Differential Gene Expression in Fluconazole-Susceptible and -Resistant Isolates of Candida albicans by cDNA Microarray Analysis. Antimicrob. Agents Chemother. 46: 3412-3417 [Abstract] [Full Text]  
  • Gunderson, S. M., Hoffman, H., Ernst, E. J., Pfaller, M. A., Klepser, M. E. (2000). In Vitro Pharmacodynamic Characteristics of Nystatin Including Time-Kill and Postantifungal Effect. Antimicrob. Agents Chemother. 44: 2887-2890 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»